Highlights
Introduction
Cerebral ischemia, is most commonly caused by blockage of the cerebral vessels, and remains a leading cause of death worldwide. Cerebral vascular occlusion often leads functional impairment, which is an economic and social burden for families. Fibrinolytic therapy with rtPA is the only American FDA-approved treatment for ischemic stroke (Hacke et al., 2008) . Unfortunately, the "time window" for rtPA treatment and risk of HT limit its clinical application (Hafez et al., 2015; Medcalf, 2011) .HT is a severe complication of AIS, which is observed in nearly 9% of reported AIS cases (Paciaroni et al., 2008) and commonly occurs in the cases with thrombolytic therapy (Fiehler et al., 2005; Molina and Alvarez-Sabin, 2009 ).
The BBB is a specialized regulator that separates the blood from the brain parenchyma. It effectively mediates the exchange of substances in the central nervous system, and its barrier structure restrains the influx of harmful substances and promotes essential nutrients to reach the brain. The primary structure of BBB contains brain endothelial cells, astrocytes, pericytes, neurons, supporting structures (microglia, oligodendrocytes), and ECM. The BBB comprises the TJs and AJs. The TJ proteins, located at the apical side of the endothelial cells, are the primary physical barrier limiting paracellular diffusion between the blood and the brain parenchyma (Abbott et A C C E P T E D M A N U S C R I P T al., 2010; Reese and Karnovsky, 1967) . Moreover, the TJ proteins are consisted of three integral protein types: claudins, occludin and junctional adhesion molecules (JAMs) (Abbott et al., 2010) . Meanwhile, the AJs, located at the basolateral side of the BBB, are largely composed of the VE-cadherin with the function of localizing and stabilizing the TJs via regulating the adhesion of endothelial cells to each other Taddei et al., 2008) .
The BBB damage in AIS is commonly considered the primary cause of HT and associated with worse stroke outcome (Brouns et al., 2011; Lorberboym et al., 2003) . Ischemic BBB disruption is regulated by different detrimental mechanisms during ischemic stroke, including via MMPs, inflammation, oxidative pathways, vesicular trafficking and so on (Sifat et al., 2017) . Pertinent interventions in the above-mentioned mechanisms have the prospect of protecting BBB from ischemia. In this review, we briefly discuss the research progress in the protective approaches to alleviating BBB damage of ischemic stroke in recent years.
1.Physical approaches to BBB protection in AIS
Oxygen inhalation treatment is commonly used in patients with AIS. However, the relationship between the protective mechanism of oxygen inhalation relative to different gas pressures or concentrations has not been clarified completely. In rat MCAO, hyperbaric oxygen treatment protects the BBB and prevents HT in hyperglycemic rats through improving energy metabolism and decreasing apoptosis, possibly involving the ATP/NAD+/Sirt1 pathway (Hu et al., 2017) . Moreover, Michalski et al. have shown similar results, namely that hyperbaric oxygen stabilizes BBB through reducing MMP-2 activation in a rat MCAO model (Michalski et al., 2011) . Furthermore, their result demonstrate that normobaric oxygenation is a promising treatment, which can reduce functional impairment and stabilize BBB during the rat MCAO experiment (Michalski et al., 2011) . There have been many other advances in normobaric hyperoxia treatment. Shi et al. have found that the normobaric hyperoxia treatment (oxygen by facemask at a flow rate of 10 L/min) can improve the neurological function of AIS patients received thrombolytic therapy at 3 days and 1 week after admission (Shi et al., 2017) . The result also suggests that normobaric hyperoxia may become an efficacious adjuvant therapy for tPA thrombolytic therapy after ischemic stroke via the neurological protective mechanism of reducing the degradation of occludin from microvasculature (Shi et al., 2017) . Another study has found that normobaric hyperoxia treatment can ameliorate BBB damage even during prolonged periods of cerebral ischemia in the rat MCAO model and can decrease neurovascular complications associated with delayed tPA treatment through inhibiting MMP-9 induction and TJ proteins degradation . As one of the most common treatments for stroke patients, oxygen inhalation treatment, both hyperbaric oxygen inhalation and normobaric hyperoxia treatment may be effective BBB protectants which may help improve neurological outcome and avoid malignant complications.
The inhibitory effect of MMPs has been found in physical approaches to BBB protection other than oxygen inhalation treatment. Hypothermia has been suggested to be an effective therapeutic approach to reducing brain injury through decreasing brain metabolic activity. New research concerning hypothermia's protective action in ischemic BBB damage has been published in recent years. Local brain cooling can decrease BBB permeability, brain edema, and improve neurological functions in the rat MCAO model after tPA administration, and this beneficial function is possibly related to the descending plasma levels of MMP-9(Cechmanek et al., 2015; Zarisfi et al., 2017) . Tang et al. also believe that combination therapy with mild hypothermia and rtPA is safe and effective because of its BBB protective mechanism of reducing endogenous tPA (Tang et al., 2013) . Hypothermia treatment is commonly used in critically ill patients at present, but the intensive effort involved and nursing costs restrict its widespread use. Isoflurane, a commonly used volatile anesthetics, has been reported as a protective agent against brain ischemia (Yu et al., 2010) . Further research affirms that isoflurane postconditioning may be a BBB protector, inhibiting tPA-induced MMP-2/9 activation in an OGD model (Kim et al., 2017) . Furthermore, another gas also has been discussed in the studies of ischemic stroke. Hydrogen sulfide, a poisonous gas that smells like rotten eggs, is increasingly being regarded as a pivotal endogenous gasotransmitter. In the ischemic stroke rat model experiment, administration of hydrogen sulfide donors may be a novel intervener to improving the safety of tPA treatment following stroke by ameliorating cerebral hemorrhage and BBB damage, and its protective function is possibly dependent on inhibiting MMP-9 . Due to complicated service conditions and uncertainty surrounding adverse effects, special gases may not be the conventional clinic treatment for stroke patients until more advantageous outcomes are confirmed. In addition, non-invasive vagus nerve stimulation also could protect BBB from ischemic damage by inhibiting MMP2/9-mediated TJ protein disruption .Based on these research results, we find that the inhibiting effect on MMPs plays a significant role in the above-mentioned physical approaches for BBB protection.
Protecting TJ proteins is another important mechanism for BBB protection. HS can remove water from the intracellular into the extracellular space by an osmotic pressure gradient, and its non-osmotic function also has been studied in recent years (Nout et al., 2009 ). 10% HS can alleviate BBB damage and decrease cerebral edema in the MCAO model by inhibiting down-regulation of ZO-1 and claudin-5 mediated by VEGF and VEGFR2 (Huang et al., 2016a) . Moreover, Cao et al. also found that HS can alleviate cerebral edema through inhibiting AQP-4 in astrocytes (Cao et al., 2012) . However, HS treatment should be administrated by electrolyte detection to reduce the risk of electrolyte disturbance aggravating brain injury. Furthermore, ischemic postconditioning is a method to make rapid and repeated intermittent interruptions of cerebral reperfusion blood flow, in order to mechanically mediate the hydrodynamics of reperfusion. Esmaeeli-Nadimi et al. have demonstrated that ischemic postconditioning (5 cycles of 10 s occlusion and 30 s reperfusion of bilateral common carotid arteries) during the reperfusion phase is a neuroprotective treatment, which ameliorates malignant hyperemia and reperfusion injury and
BBB damage and improves neurological functions . In line with this research, another study had similar results concerning the neuroprotective effect of ischemic postconditioning. The postconditioning stabilizes BBB integrity by increasing the expression of TJ proteins claudin-5 and occludin and attenuating the injury to neurons, astrocytes and brain endothelial cells (Han et al., 2014) .
Other mechanisms of ischemic BBB protection have also been studied in physical approaches recently. Electroacupuncture, a Chinese traditional acupuncture therapy combined with modern electrotherapy, is proposed as a protective approach against transient cerebral ischemia (Wang et al., 2009) . Electroacupuncture pretreatment reduces BBB permeability and brain edema by inhibiting the expression of p-caveolin-1 in the endothelial cells . Physical intervention of local vessels or nerves seems to effectively reduce systemic adverse reaction, but more reliable evidence is needed to support these conclusions. In addition, the standard of physical strength and frequency of the treatment require clarification and further work. The main BBB protective mechanisms of the physical approaches mentioned above are summarized in the figure 1 and table 1.
2.Chemical agents regulating BBB permeability in AIS
2.1 Clinical drugs regulating BBB permeability in AIS 3-n-butylphthalide(trade name: Butylphthalide Soft Capsule) pretreatment remarkably reduces BBB damage and brain edema in an MCAO model, and its beneficial effect is related to decreasing reactive ROS, MDA and increasing SOD activity . Butylphthalide has been used in the treatment of AIS patients, and more beneficial evidence will further confirm its important role in ischemic stroke treatment. Diabetes is one of the risk factors for cerebral infarction, and metformin is a commonly used drug for type 2 diabetes and other metabolic diseases (Martin-Montalvo et al., 2013) . The potential neuroprotective function of metformin has become a research hotspot recently. Liu et al. made progress demonstrating that metformin protects against ischemic BBB damage by inhibiting ICAM-1 mediated by the AMP-activated kinase signaling pathway, along with alleviating neutrophil infiltration . It seems that metformin may be a better choice for diabetic patients in order to improve outcome from ischemic BBB injury. Based on these evidences, the anti-oxidative and anti-inflammation effects are the significant mechanisms in the clinical drugs regulating BBB permeability in AIS.
Other than the anti-oxidative and anti-inflammation effects, malignant contributing factors to ischemic BBB damage are the proteolysis of MMPs, which can degrade TJ proteins causing BBB hyperpermeability and cerebral edema. Thus, drugs inhibiting MMPs may be promising BBB protectants reducing brain edema and HT.
Propofol, a widely used anesthetic, reduces the BBB permeability and brain edema in an ischemic stroke rat model through down-regulating MMP-9, AQP-4 and pJNK . By suppressing the activity of serine/threonine protein phosphates, norcantharidin may have anticancer agent properties (Hill et al., 2008) . Furthermore, a recent study demonstrates that intraarterial norcantharidin significantly decreases the infarct volumes and BBB damage via inhibiting MMP-9 expression in an MCAO model (Khan et al., 2016) . However, systematic side effects of anticancer drugs could be obstacles to clinical application in AIS patients. Minocycline, a second generation tetracycline, is reported as a neuroprotective agent in previous studies (Buller et al., 2009 ). An updated experiment further confirms that minocycline improves hypoxia-induced BBB disturbance via inhibition of HIF-1α, which is mediated by the sirtuin-3/proline hydroxylase-2 degradation pathway, along with down-regulation of MMP-2, MMP-9 and VEGF and up-regulation of TJ proteins . These drugs may be applied in stroke patients for ischemic BBB treatment in the future if evidence of their benefit is proven clinically.
In a rat MCAO model study, retinoic acid stabilizes the BBB structure by reserving ZO-1 and VE-cadherin expression . It is claimed that retinoic acid's protective role is related to the RA receptor in an OGD model . In the recent study, ascorbic acid is recognized as a neuroprotectant, which protects the BBB and reduces brain edema through decreasing up-regulation of MMP-9 induced by ischemia and rtPA administration . Based on these research results, retinoic acid and ascorbic acid may be promising adjuvant therapies to attenuate the side effects of delayed application of rtPA in cerebral ischemia. Previous studies show that progesterone stabilizes the BBB in the ischemic stroke model through inhibiting MMP and the inflammatory response (Ishrat et al., 2010) . Furthermore, Won et al. conducted an in-depth study and claim that progesterone plus tPA treatment can reduce BBB permeability and HT by decreasing MMP-9 and VEGF expression (Won et al., 2014) . The researchers believe that progesterone may become a neuroprotective adjuvant for delayed tPA thrombolytic therapy by reducing its side effects. However, hormone abnormalities may be the restricting factor for its application in stroke patients, particularly males. Urokinase is another thrombolytic drug used in China. Polyethylene glycol, a hydrophilic polymer with high biocompatibility, is approved by the American FDA for clinical application (Roberts et al., 2002) .Recent research demonstrates that treatment with polyethylene glycol-conjugated urokinase nanogels can activate the fibrinolytic system, alleviate brain injury and stabilize BBB in a rat cerebral ischemia model through inhibiting MMP9 expression and reserving TIMP-1 and claudin-5 (Cui et al., 2016) . Based on the above evidence, we speculate that drugs which inhibit MMPs may become BBB protectants in an ischemic stroke model.
Erythropoietin, a glycoprotein hormone, which stimulates and promotes the production of red blood cells, may play a protective role in cerebral ischemic models with multiple mechanisms (Li et al., 2007) . Zhou et al. recognize erythropoietin as a BBB protectant possibly through increasing the expression of p-Connexin43 and
improving GJIC in the MCAO model . The main BBB protective mechanism of the clinical drugs mentioned above are summarized in figure 2 and table 2.
Chemical compounds regulating BBB permeability in AIS
Resistin, a cysteine-rich polypeptide, is mainly produced by macrophages in humans (Jung et al., 2006) . In the mouse MCAO model study, resistin elicits a beneficial role on infarct size, BBB permeability and neurological function in a dose-dependent approach by suppressing apoptosis and oxidative stress (Behrouzifar et al., 2018) . Furthermore, DSS is a newfangled synthetic material resulting from the modified structure of daidzein. DSS confers protection against an ischemic cerebral insult via promoting the expression of Bcl-2 and inhibiting the expression of Bax and caspase-3 at a dose range of 0.5-2.0 mg/kg .In this study, the Evans blue content of brain tissues is remarkably decreased by the administration of DSS, indicating its BBB protective effect in ischemic brain injury .Therefore, the anti-apoptosis effect may be another key factor in protecting against ischemic BBB damage via the related chemical compounds.
In recent years, inhibitory effect on MMPs has been found in many chemical compounds, which show a neuroprotective effect on ischemic BBB damage. DeMars et al. conducted a rat experiment with L-902,688 (prostanoid EP4 receptor agonist) and demonstrate that the EP4 agonism inhibits pro-inflammatory IL-1β, MMP-3/9, reserves TJ proteins and then protects BBB from the ischemic damage with a better long-term neurological prognosis (DeMars et al., 2018) . Previous research indicates that the coumarin derivative IMM-H004 (7-hydroxy-5-methoxy-4-methyl-3-[4-methylpiperazin-1-yl]-2H-chromen-2-one) elicits beneficial effects on OGD model experiment via scavenging ROS and inhibiting the apoptotic pathway (Ji et al., 2014) . IMM-H004's BBB protective function in ischemic brain damage is confirmed, and the related mechanism is the reduction of MMP-9 and AQP-4, which contributes to the degradation of TJ proteins (Niu et al., 2017) . GW0742, a PPAR-β/δ agonist, decreases BBB permeability, MMP-9 expression and reserve TJ proteins in the rat MCAO model (Chehaibi et al., 2017) .
There are a large number of studies supporting the observation that HSP27 elicits a protective effect in various organs against stress (Vidyasagar et al., 2012) . Phosphorylated HSP27 is indicated as a brain protectant in the rat MCAO model via inhibiting apoptosis and inflammation (Shimada et al., 2014; Teramoto et al., 2013) . Furthermore, Shimada et al. demonstrate that phosphorylated recombinant HSP27 not only decreases infarct volume, brain edema, neurological deficits and mortality, but also reduces hemorrhagic transformation and stabilizes BBB from ischemic damage induced by up-regulated MMP-9 activity in the mouse MCAO model that received tPA treatment (Shimada et al., 2018) . Pinocembrin(5,7-dihydroxyflavanone),a natural flavonoid compound, confers protection against ischemic brain injury through
inhibiting apoptosis and reversing autophagy in a previous study (Zhao et al., 2014) . Ma et al. have implemented a further experiment and certify that pinocembrin pretreatment remarkably protects BBB from ischemic damage, accompanied with inhibition of MMP-2/9 activation, reservation of TJ protein and reduction of phosphorylation of PDGFR?? (Ma et al., 2018) . NAD is a coenzyme, which plays a basic role in the mitochondrial electron transfer reactions (Rich, 2003) . Nicotinamide mononucleotide, an NAD supplement, is indicated as a protective agent to ameliorating tPA-induced HT and BBB injury by inhibiting the activity of MMP2/9 . Recombinant annexin A2, a cell-surface protein, may be an another MMP inhibitor, which has been demonstrated as being beneficial as an auxiliary approach to enhancing tPA thrombolytic efficacy and reducing its potential complications by inhibiting MMP-9 activity Jiang et al., 2015) . Bryostatin is another protective agent with inhibiting MMP-9 effect against ischemic BBB injury in the MCAO model (Tan et al., 2015; Tan et al., 2013) . Based on the aforesaid research evidence, inhibiting MMPs is possibly the main mechanism for protecting BBB injury among related chemical compounds. The chemical compounds with inhibitory effect on MMPs have potential to be BBB protectants in the future.
Other protective mechanisms have also been found in neuroprotective compounds. Huang et al. found another BBB protectant called D-allose in the ischemic stroke model. D-allose is one of rare sugars and exists in nature in limited quantities (Lim and Oh, 2011) .It can significantly up-regulate PPARγ, inhibit TNF-α, NF-κB and reserve TJ proteins, along with down-regulation of ICAM-1, vascular cell adhesion molecule-1 and CD11b/CD18 (Huang et al., 2016b) . Recent research results demonstrate that 4-methoxy benzyl alcohol, an active compound in Gastrodia, decreases the ischemic brain injury through down-regulating BBB permeability, inhibiting NOS and AQP-4 expression and reserving TJ protein in the rat ischemic stroke model (He et al., 2017) . Apelin-13 is one of the most bioactive forms of Apelin, which is the first identified peptide in its 36-amino acid isoform in bovine stomach extracts (Tatemoto et al., 1998) . Previous studies have demonstrated that Apelin-13 confers a neuroprotective effect in an MCAO model by inhibiting neuroinflammation (Xin et al., 2015) . Chu et al. explored this further and demonstrate that Apelin-13 stabilizes BBB from ischemic damage both morphologically and functionally, and its beneficial effect is potentially due to the up-regulation of AQP4 and activation of ERK and PI3K/Akt pathways (Chu et al., 2017) . The main BBB protective mechanism of the chemical compounds above are summarized in figure 3 and table 3.
3.Traditional Chinese medicine and its extracts regulating BBB permeability in AIS
TCM has been used in Asian countries, especially China for treating a variety of diseases. TCM preparation, Chinese materia medica and their active compounds show potential to ameliorate ischemia/reperfusion-induced brain damage (Sun et al., 2015a) . There are many studies concerning TCM's BBB protective function reported in recent years.
Patchouli alcohol, a natural extract from the herb Pogostemonisherba, can attenuate BBB dysfunction in the ischemic stroke model, and its protective mechanism is possibly related to the down-regulated expression of TNF-α and IL-1β mediated by MAPK signaling pathways (Wei et al., 2018) . Salvianolic acid A(compounds extracted from Salvia Miltiorrhiza Bge) is another potential therapeutic compound which may treat BBB damage in AIS. The mechanism of its neuroprotective effect is not only related to inhibiting the degradation of TJ proteins induced by MMP-9, but also involves the inhibition of NF-κB p65 activation and inflammation response . Magnolol, an another TCM extract, becomes a promising BBB protectant by inhibiting cerebral inflammation in ischemic stroke . Furthermore, Vitexin plays a beneficial role on the BBB disturbance in an ischemic neonatal rats model by regulating the Na + -K + -Cl − co-transporter1/F-actin signaling pathways, accompanied with down-regulated inflammatory cytokine and neutrophil infiltration (Luo et al., 2018) . Therefore, anti-inflammatory effects are some one of the significant mechanisms in TCM related treatment for ischemic BBB damage.
The activation of MMP is a major contributing factor for ischemic BBB breakdown, and MMP inhibitors are usually regarded as BBB protectants. Leonurine and crocin, two compounds extracted from natural herbs, are MMP antagonists, which can down-regulate the MMP expression, elevate TJ proteins and stabilize BBB in a rat MCAO model (Zhang et al., 2017a; Zhang et al., 2017c) . Another famous natural compound, Baicalin, has also become the focus of recent research. Baicalin, isolated from the root of baicalensis, is considered an antagonist against ischemic BBB damage with delayed tPA therapy, depending on scavenging peroxynitrite and inhibiting MMP-9 activation . Previous studies claimed that STS, a water-soluble component extracted from herb Salviae miltiorrhiza, can stabilize the BBB against leukocyte-associated hypoxia-reoxygenation injury (Zhang et al., 2010) . Over the last two years, further clinical research indicated that STS possibly inhibits MMP-9 and then ameliorates BBB disruption in AIS patients following rtPA thrombolysis . Tong-Qiao-Huo-Xue Decoction is a commonly used TCM prescription, which was recently confirmed as an ischemic BBB protectant by inhibiting MMP-9 and AQP-4 . Methylophiopogonanone A, an active component extracted from Ophiopogon japonicas, attenuates BBB injury by inhibiting MMP-9 and protecting tight junction proteins . Among these studies, inhibiting the activities of MMPs are the key mechanisms in TCM treatment for BBB protection.
As well as inhibiting MMP-9, leonurine also protects against ischemic BBB by its anti-oxidative function of inhibiting NOX-4 (Zhang et al., 2017a) . Another extract
from Picrorrhiza kurroa Royle called Picroside II protects against ischemic BBB damage by suppressing the oxidative signaling pathway (Zhai et al., 2017) . Thus, anti-oxidative stress is another significant mechanism in TCM's neuroprotection for BBB damage.
Other important mechanisms in TCM treatment for BBB injury have been studied recently. Tongxinluo (TXL), a traditional Chinese medicine, has been widely studied for its neuroprotective role on BBB damage in cerebral ischemia in last few years. Yu et al. demonstrate that TXL shows neuroprotection against BBB damage by activating the MEK1/2/ERK1/2/p90 ribosomal S6 kinase pathway . Meanwhile, another study supports its BBB protective action against brain edema (Cai et al., 2016) , and its protective function is possibly related to activation of ERK1/2 and restoration of TJ proteins disrupted by oxidized low-density lipoprotein (Chang et al., 2017) . Buyang Huanwu Decoction treatment elicits a protective role on ischemic stroke through its anti-inflammation and anti-apoptosis effect at the genetic level (Wang et al., 2011) . Moreover, Buyang Huanwu Decoction is further confirmed as a BBB protectant via the inactivation of GSK-3 and Tau regulated by down-regulated phosphorylation . Salidroside, an extract from a traditional Tibetan medical plant named Rhodiolarosea, may be an effective thrombolytic adjuvant therapy, which can alleviate BBB damage in the delayed treatment of tPA through activating PI3K/Akt signaling in vivo and in vitro (Zuo et al., 2018) . Moreover, Ginsenoside-Rg1 is a kind of saponin component extracted from ginseng, and it has been discovered as the neuroprotective TCM for reducing BBB permeability in an ischemic stroke model partly through inhibiting PAR-1 expression (Xie et al., 2015) . TCM is a significant treatment choice for clinical patients, and neuroprotection may bring benefit to the brain injury. However more evidence is needed to support its clinical application for ischemic BBB damage. The main BBB protective mechanism of TCM and its extracts above are summarized in figure 4 and table 4.
4.MicroRNA regulating BBB permeability in AIS
MicroRNAs (miRNAs), composed of 20-24 nucleotides, are characterized by single-stranded non-coding (nc)RNA (Bartel, 2004) .MicroRNAs confer an important regulative effect on molecular processes after cerebral ischemia (Jeyaseelan et al., 2008; Uhlmann et al., 2017) . There are a large number of studies indicating that the miRNA can contribute to BBB injury in ischemic stroke in recent years.
MiRNA-21 is indicated as a BBB protectant against cerebral ischemic/reperfusion damage through inhibiting the MAPK signaling pathway (Yao et al., 2018) . Meanwhile, overexpression of miRNA-21 also elicits a beneficial role on spinal cords during ischemia-reperfusion injury via down-regulating proapoptotic proteins (He et al., 2016) . MiR-124a is the most abundant miR in brain tissue, and it contributes to the neuronal differentiation during central nervous system development (Sun et al., 2015b) .In clinical studies, serum miR-124 expression is
remarkably decreased in patients within 24 hours after ischemic stroke, along with increased infarct volume and MMP9 expression .Up-regulation of miR-124a expression induced by D-4F(an apolipoprotein-A1 mimetic peptide) is demonstrated as a protectant through decreasing BBB leakage and improving functional outcome in a rat stroke model . A previous study demonstrated that acute ischemic stroke down-regulates the expression of miR-29b, which contributes to neuron survival and cerebral infarction (Khanna et al., 2013) . Meanwhile, miR29b is indicated as a regulator of BBB dysfunction through regulating MMP9 activity (Kalani et al., 2014) . Furthermore, Wang et al. have certified that overexpression of miR-29b can stabilize BBB structure and reduce brain edema possibly through regulating the expression of AQP4 .
The MicroRNAs with detrimental effect on ischemic BBB damage have also been studied in recent years. Ischemic stroke induces the expression of MiR-130, and its antagonist plays a protective role in the brain damage and decreases the size of the cerebral infarct (Sepramaniam et al., 2012) . Furthermore, recent studies demonstrate that miR-130a elicits detrimental effect on BBB integrity during the ischemic damage, and its regulating action is related to Homeobox A5-induced occludin down-regulation . Meanwhile, MiR-210 is also indicated as having a harmful role in the hypoxic-ischemia brain injury, and the inhibition of miR-210 can remarkably reduce BBB damage and brain edema following hypoxic-ischemia damage . MiR-150 confers vital regulative action on endothelial functions and contributes to the tumorigenesis and inflammation (Luo et al., 2013; Yan et al., 2015) . Overexpression of miR-150 can increase endothelial cell mortality and decrease claudin-5 expression by directly targeting angiopoietin receptor Tie-2, along with worse BBB function after a focal ischemic insult (Fang et al., 2016) . Based on these studies, MicroRNA intervention can regulate BBB permeability by different mechanisms in an ischemic stroke model. Further studies may support microRNA as a promising BBB regulator in ischemic brain injury.
Neural stem cell therapy and BBB permeability in AIS
Treatment with transplantation of NSCs is known to be a BBB protectant against ischemic brain damage during ischemic reperfusion according to recent reports. Rats in the ischemic stroke model transplanted with human induced pluripotent stem cell-derived NSCs show a decreased BBB permeability, which is associated with the reservation of the TJ protein ZO-1 and the attenuation of MMP-9 (Eckert et al., 2015) . Similarly, Huang et al. indicate that transplantation of human NSCs can reduce infarct volume and ameliorate BBB damage in the rat MCAO models (Huang et al., 2014) . This rapid therapeutic effect of NSCs is possibly associated with its anti-inflammatory function, which is supported by the down-regulating of inflammatory factors such as IL-6, IL-1β, and macrophage inflammatory protein-1α (Huang et al., 2014) .
In recent research, transplantation of adjudin-preconditioned NSCs has been demonstrated to be an enhanced protectant against the ischemic damage in the rat MCAO model by decreasing infarct volume and BBB permeability(Zhang et al.,
. In this study, preconditioning of adjudin, a small molecule compound, can promote NSC survival in vitro and help NSCs to resist neuroinflammation and oxidative stress, resulting in improved therapeutic efficiency of NSCs in an ischemic mouse model (Zhang et al., 2017b) . All these results above prove that NSCs treatment is able to stabilize the integrity of the BBB and elicits a neuroprotective effect on cerebral ischemic injury following stroke.
6.Methods of aggravating BBB injury in AIS
Some remedies which have deleterious effects on ischemic BBB damage have also been reported recently. Hypoxic preconditioning could aggravate BBB injury and brain edema possibly via the VEGF related pathway in the early stages of ischemic stroke (Chi et al., 2017) . As well as oxygen uptake, body temperature changes may be a detrimental factor for ischemic BBB damage. Hypothermia followed by rapid rewarming could enhance BBB permeability in ischemic stroke, accompanied with increased MMP-9 expression and tight junction damage . Furthermore, a high salt diet significantly exacerbated BBB damage via a p38/MAPK/SGK1-dependent pathway in cerebral ischemia . In addition, a high-iron diet also exacerbated the risk of HT after early tPA administration (Garcia-Yebenes et al., 2018) . Meanwhile, acute hyperglycemia could aggravate BBB impairment possibly through enhancing the early release of high mobility group box-1 from ischemic brain tissue . It seems that a reasonable dietary habit could relieve BBB injury when stroke occurs. Interleukin-23 could also worsen the BBB damage induced by OGD, accompanied with more serious neuron damage and astrocyte swelling. Moreover, smoking is not only a risk factor of stroke, but also a possible detrimental factor to ischemic BBB damage. Some research confirms that nicotine exacerbates brain edema during focal ischemic conditions, possibly related to altered BBB permeability (Abbruscato et al., 2002; Abbruscato et al., 2004; Paulson et al., 2010) . A better understanding of the mechanisms imposing deleterious effects on ischemic BBB injury may also provide a potential therapeutic target in stroke research.
Conclusion
In summary, BBB damage is a pivotal pathological process in ischemic brain injury, and the essential factor for HT induced by severe stoke and thrombolytic therapy. Thus, protection of BBB is a significant therapeutic target, which not only offsets the side effect of rtPA, but improves prognosis of severe stoke. In this article, we briefly reviewed recent research progress in the approaches to regulating BBB permeability in the post-stroke brain, including physical approaches, chemical agents,
traditional Chinese medicines and extracts, neural stem cell therapy and microRNA intervention. Based on the above-mentioned research evidence, we find that the inhibiting effect on MMPs, anti-oxidative effect and anti-inflammation effect are the main effect mechanisms among the aforesaid BBB protectants, especially the inhibitory effect on MMPs. Acquiring a better understanding of the newer BBB protective approaches will pave the way for exploring an effective and safe therapeutic method for ischemic stroke patients.
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